Reposted from the College of Engineering.
University of Utah researchers have characterized a protein that may help protect spinal discs from age-related damage, pointing to a possible direction for future back pain treatments.

Using CRISPR to target ZNF865, also known as BLST, in human cells and mouse and rat models, the interdisciplinary team showed how increasing or decreasing BLST levels affected spinal disc health.
Led by Robby D. Bowles, an associate professor of biomedical engineering, the study is the first functional characterization of the gene and protein. Additional preclinical studies and, eventually, clinical trials are needed to determine whether targeting BLST with CRISPR could be safe and effective in people.
"This paper directly shows a novel understanding that DNA damage is a driver of back pain, and that we can regulate BLST therapeutically with CRISPR," Bowles said. "Back pain is the number three leading cause of disability as measured by disability-adjusted life years, only behind cardiac disease and drug use disorders."
Bowles and members of his lab in the John and Marcia Price College of Engineering collaborated with researchers specializing in orthopaedics and arthritis at the Spencer Fox Eccles School of Medicine, and with other university researchers at Huntsman Cancer Institute at the University of Utah. The mechanisms identified in the study could also inform research into DNA damage associated with cancer.
The study, published in Aging Cell, found that levels of BLST were lower in older and damaged spinal discs, the cushion-like structures between vertebrae that allow the spine to move.
"It has been the highlight of my career to work on a protein that was unknown and be the first to identify its function," Bowles said. "While this work focuses on its application to back pain, the mechanisms identified have the potential to be applied to treat cancer, neurodegeneration, and any disease in which DNA damage is involved."
Using the gene-editing tool CRISPR, researchers restored BLST production in human disc cells, reducing signs of cellular aging and DNA damage. Conversely, reducing BLST activity in rodents led to disc degeneration and pain-related behaviors.
These findings suggest that BLST helps maintain healthy disc tissue by protecting cells from damage and dysfunction as they age.
Although the discovery could eventually lead to new ways to prevent or treat age-related back pain, researchers must determine whether targeting BLST can be safe and effective in people.
Further research is also needed to determine whether the same mechanisms are involved in age-related cancers.
"The fact that a single gene can restore normal cell function and reverse aging-related effects is incredible," said Jason Gertz, a professor in the Department of Oncological Sciences and co-leader of the Genomics, Epigenetics, and Metabolism Program at Huntsman Cancer Institute. "BLST is widely expressed across tissues and could be a promising target for cancer treatment and prevention, since boosting BLST activity should improve the repair of DNA damage and the overall health of aging cells."
Published online Oct. 9, the study is titled "ZNF865 (BLST) a Novel Regulator of DNA Damage and Cell Senescence in Back Pain." Coauthors include Bowles Pain & Engineered Therapeutics Lab members Christian Lewis, Hunter Levis, Jonah Holbrook and Molly Czachor; Jacob T. Polaski, a postdoctoral researcher at Huntsman Cancer Institute; Josh Mizels and Brandon Lawrence of the Department of Orthopaedics; Sarah E. Gullbrand of the University of Pennsylvania; Timothy D. Jacobsen and James C. Iatridis of the Icahn School of Medicine at Mount Sinai's Department of Orthopaedics; and Brian Diekman of the University of North Carolina at Chapel Hill. The National Institute of Arthritis and Musculoskeletal and Skin Diseases funded the work.